Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene study aims to boost kidney transplant success for african americans

NCT ID NCT03615235

Knowledge-focused Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

The APOLLO study looks at how variations in the APOL1 gene, common in people of African ancestry, affect kidney transplant outcomes. Researchers are testing DNA from 5,000 kidney donors and recipients to see if certain gene variants lead to faster kidney failure or harm living donors. The goal is to make transplants safer and more successful for this group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better match donors and recipients to improve kidney transplant survival and reduce risks for living donors.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and results depend on large-scale data collection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2019

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Thirteen APOLLO Clinical Centers (CCs) will prospectively enroll eligible living kidney donors and recipients of kidney transplants from eligible living and deceased kidney donors at all transplant programs in the continental United States including Puerto Rico. The APOLLO Scientific and Data Research Center (SDRC or Coordinating Center) will support and participate in studies determining the impact of donor and recipient APOL1 genotypes on kidney transplant outcomes in recipients of a kidney transplant from a donor with recent African ancestry, and follow African ancestry living kidney donors for changes in vital status, kidney function and proteinuria. In this protocol, recent African ancestry is broadly defined as African American, Afro-Caribbean, Hispanic black, and African.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for Living Donors: * Living kidney donors with self-reported recent African ancestry (defined as African American, Afro-Caribbean, Hispanic black or African) will be eligible for inclusion. Exclusion Criteria for Living Donors: * Participants who are unable or unwilling to provide informed consent. Enrollment and bio sample collection from deceased donors at OPOs ended on May 31, 2023 and recruiting kidney transplant recipients ended on June 15, 2023. Phase II started on 9/1/2023 and only Living Donors will be recruited for an additional 2 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney disease, chronic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome kidney disorder kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney disease, chronic Kidney diseases Kidney failure

Contacts and locations

Locations

  • Cleveland Clinic

    Cleveland, Ohio, 44106, United States

  • Columbia University Irving Medical Center

    New York, New York, 10032, United States

  • Duke University

    Durham, North Carolina, 27705, United States

  • Emory University School of Medicine

    Atlanta, Georgia, 30322, United States

  • Ichan School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Johns Hopkins University

    Baltimore, Maryland, 21205, United States

  • Joslin Diabetes Center / Harvard University

    Boston, Massachusetts, 02215, United States

  • Saint Louis University Center for Transplantation

    St Louis, Missouri, 63104, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35233, United States

  • University of California San Francisco

    San Francisco, California, 94143, United States

  • University of Maryland School of Medicine

    Baltimore, Maryland, 21201, United States

  • University of Miami / Miami Transplant Institute

    Miami, Florida, 33133, United States

  • University of Michigan Medicine

    Ann Arbor, Michigan, 48109, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • University of Wisconsin - Madison

    Madison, Wisconsin, 53792, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

  • Wake Forest School of Medicine

    Winston-Salem, North Carolina, 27157, United States

  • Weill Cornell Medicine

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.